Report Highlights

Softgel Capsules in the United States: Market Overview

The U.S. softgel capsule market reached USD 1.12 billion in 2024 and differs sharply from the global norm. Dietary supplements account for the majority of domestic demand, with fish oil, vitamin D, CoQ10 and probiotic-oil blends driving volume, whereas global demand leans toward pharmaceutical fill-finish in Europe and Asia. Gelatin shells still hold most volume, but the U.S. is the fastest adopter of plant-based starch and carrageenan shells.

Structurally, the market is concentrated at the contract manufacturing layer. Catalent operates softgel lines at its Bloomington, Indiana site, and Lonza's Capsugel network supplies shell technology to brand owners, meaning most U.S. supplement brands are price-takers on capacity rather than owners of encapsulation assets. Private-label contract manufacturers in New Jersey, California and Utah compete on fill speed and minimum order size, creating a fragmented brand layer above a consolidated capacity base.

Growth Drivers in U.S. Softgel Capsules

Three demand drivers stand out. First, the Dietary Supplement Health and Education Act of 1994 keeps supplement formulation flexible, enabling rapid SKU expansion in omega-3, vitamin D and botanical oil formats. Second, ageing demographics matter: the Census Bureau projects the U.S. population aged 65 and over to exceed 73 million by 2030, sustaining demand for cardiovascular, cognitive and bone-health softgels that dominate older-consumer supplement aisles.

Third, the generic pharmaceutical pathway is opening softgel volume. ANDA filings reviewed under GDUFA timelines have enabled generic omega-3 acid ethyl ester softgels following Lovaza's exclusivity expiry, while OTC ibuprofen and acetaminophen softgels continue to gain shelf space. Liquid-filled formats are marketed as faster absorbing than tablets, reinforcing category growth in women's health and sports nutrition.

Market Restraints and Entry Barriers

Gelatin sourcing is the first barrier. Bovine and porcine gelatin supply is concentrated among a small number of processors, led by Darling Ingredients' Rousselot and Gelita, and U.S. buyers face price volatility alongside kosher and halal certification demands. Entrants must also source USP-grade gelatin and document TSE/BSE compliance before commissioning a line, adding several months to validation.

Capital intensity and compliance form the second barrier. A commercial softgel encapsulation line typically requires an investment near USD 10 million before validation, and 21 CFR Part 111 requires identity testing of every incoming dietary ingredient. Incumbent contract manufacturers with clean FDA Form 483 histories hold a trust advantage that new entrants cannot replicate quickly, particularly when national retailers demand audited supplier files.

Market Opportunities in U.S. Softgel Capsules

Plant-based softgel shells represent the nearest large opportunity. Non-gelatin shells remain a niche, but vegan-positioned supplement launches are expanding fastest, and we estimate an addressable pool of USD 180 million for starch- and carrageenan-based softgels in the U.S. by 2026. Contract manufacturers with validated starch-based lines can capture this demand, and sourcing from domestic suppliers shortens qualification cycles compared with imported fill.

Generic prescription softgels offer a second window. Omega-3 acid ethyl ester softgels and cyclosporine softgels together represent an addressable generic pool estimated at USD 340 million in 2025. Entrants with ANDA-ready formulation and dissolution data, filed under standard GDUFA review goals of roughly ten months, can reach pharmacy shelves ahead of late-cycle competitors.

Regulatory and Policy Environment

The Dietary Supplement Health and Education Act of 1994 places supplement manufacturers under FDA post-market oversight, while the FDA Food Safety Modernization Act of 2011 and 21 CFR Part 111 set cGMP requirements administered by the FDA Office of Dietary Supplement Programs. New dietary ingredients require premarket notification at least 75 days before marketing, and Proposition 65 warnings under the Safe Drinking Water and Toxic Enforcement Act of 1986 apply to listed compounds in softgels sold in California.

Pharmaceutical softgels fall under the Hatch-Waxman Act and ANDA review by the FDA Office of Generic Drugs, with standard review goals of ten months. Subsidies are state-level rather than federal: the New Jersey Economic Development Authority's Grow New Jersey programme and Indiana Economic Development Corporation tax incentives have supported encapsulation capacity expansions, with awards conditioned on job creation milestones over three to five years. The Federal Trade Commission enforces advertising claims under Section 5 of the FTC Act.

Long-Term Outlook for Softgel Capsules in the U.S.

By 2032 the U.S. softgel capsule market is projected to reach USD 1.68 billion, with plant-based shells gaining an increasing share of new supplement SKUs. Dietary supplements will remain the volume anchor, while generic prescription softgels grow as patent expiries accumulate across omega-3 and immunosuppressant categories. Contract manufacturing capacity will stay concentrated among a few multinational operators.

Consolidation pressure will intensify. Procaps Group and mid-sized U.S. private-label manufacturers will compete for brands seeking domestic supply chains, while trade policy on imported gelatin and raw materials will shape sourcing decisions. Entrants that build plant-based qualification and secure FDA-compliant capacity early will hold durable margins by the end of the forecast period.